AxoGen (NASDAQ:AXGN) received a $26.00 price target from equities research analysts at Cantor Fitzgerald in a note issued to investors on Monday, TipRanks reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 27.08% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. ValuEngine downgraded AxoGen from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. BidaskClub downgraded AxoGen from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Finally, BTIG Research upgraded AxoGen from a “neutral” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Monday, March 25th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $38.00.

AXGN stock traded down $0.38 during mid-day trading on Monday, reaching $20.46. 10,232 shares of the stock traded hands, compared to its average volume of 376,793. AxoGen has a 52-week low of $14.13 and a 52-week high of $56.85. The firm has a market capitalization of $811.61 million, a PE ratio of -37.89 and a beta of 0.17.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Tuesday, February 26th. The medical equipment provider reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The firm had revenue of $23.40 million for the quarter, compared to analysts’ expectations of $23.40 million. AxoGen had a negative net margin of 26.68% and a negative return on equity of 15.77%. AxoGen’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.07) earnings per share. As a group, analysts forecast that AxoGen will post -0.61 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of AXGN. Oppenheimer Asset Management Inc. acquired a new position in AxoGen during the fourth quarter valued at approximately $77,000. NumerixS Investment Technologies Inc bought a new stake in shares of AxoGen in the fourth quarter valued at approximately $131,000. Citigroup Inc. boosted its position in shares of AxoGen by 17.4% in the fourth quarter. Citigroup Inc. now owns 9,905 shares of the medical equipment provider’s stock valued at $202,000 after acquiring an additional 1,467 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in shares of AxoGen by 356.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,929 shares of the medical equipment provider’s stock valued at $223,000 after acquiring an additional 8,536 shares during the period. Finally, Legal & General Group Plc boosted its position in shares of AxoGen by 5.8% in the fourth quarter. Legal & General Group Plc now owns 12,826 shares of the medical equipment provider’s stock valued at $262,000 after acquiring an additional 702 shares during the period. Institutional investors own 89.19% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Story: Momentum Investing

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.